Virtual Reality Therapy for Mal de Débarquement Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for Mal de Débarquement Syndrome (MdDS), a condition causing constant rocking or swaying sensations. The trial will test whether virtual reality can improve symptoms that often recur or resist current treatments. Participants will be divided into groups to try various approaches, including the DevRobust Treatment (a virtual reality-based visual-vestibular therapy), visual desensitization, and methods to manage gravitational pull sensations. This study may suit those diagnosed with MdDS who notice symptom improvement when passively in motion, such as riding in a car. As an unphased trial, it offers a unique opportunity to explore innovative treatments for MdDS symptoms.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that virtual reality (VR) technology is being tested to help people with Mal de Débarquement Syndrome (MdDS), a condition affecting balance and causing feelings of movement. In earlier studies, VR goggles improved symptoms such as dizziness and balance issues. About half of the participants experienced long-term relief, with some even fully recovering.
Regarding safety, VR treatments have generally been well-received. They use visual motion to help the brain adjust, and previous studies have found no major safety issues. This makes VR a promising and potentially safe option for treating MdDS.12345Why are researchers excited about this trial?
Researchers are excited about this trial for Mal de Débarquement Syndrome because it explores innovative uses of virtual reality (VR) and visual therapies. Unlike standard treatments that primarily focus on medications or vestibular therapy, this study investigates the potential of VR goggles and visual desensitization protocols to re-adapt the vestibulo-ocular reflex (VOR). The unique aspect here is the use of full-field optokinetic stimulation (OKS) and VR settings, which may offer more immersive and targeted therapy options. By examining these cutting-edge techniques, researchers hope to uncover new, effective ways to manage and treat the symptoms of this challenging condition.
What evidence suggests that this trial's treatments could be effective for Mal de Débarquement Syndrome?
Research has shown that a special therapy for Mal de Débarquement Syndrome (MdDS) can help about 50% of patients feel significantly better or even symptom-free. This therapy retrains the brain to better handle balance and motion signals. In this trial, participants will join different groups to test various approaches, including the use of virtual reality (VR) to deliver the therapy. Recent studies have explored VR, and it appears to work as well as traditional methods. VR simplifies the exercises needed for improvement. Early research with VR has shown promise in enhancing balance and reducing dizziness, which are main symptoms of MdDS.12345
Who Is on the Research Team?
Sergei Yakushin
Principal Investigator
Ichan Scool of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
This trial is for individuals with Mal de Débarquement Syndrome who feel better when in passive motion. It's not suitable for those with claustrophobia, certain neurological disorders like MS or epilepsy, abnormal inner ear function tests, injuries affecting mobility without support, prior VOR readaptation treatment, or high anxiety levels.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VOR readaptation treatment with either full-field OKS or VR goggles for 1-2 hours a day over 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at baseline and 6 months
Extension
Participants may receive additional treatment focusing on VID or MS susceptibility if symptoms persist
What Are the Treatments Tested in This Trial?
Interventions
- DevRobust Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
New York University
Collaborator
Brooklyn College of the City University of New York
Collaborator
Ohio University
Collaborator
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator